Acute Effect of modeRate-intensity aerOBIc Exercise on Colon Cancer Cell Growth

Study Overview
=================
Brief Summary
-----------------
This study involves drawing blood samples from men before and after they perform 30-minutes of moderate-intensity aerobic exercise. The investigators will evaluate whether adding the exercise serum to colon cancer cells in a dish can reduce the growth of the cells compared to the resting serum. Note: serum is the liquid part of the blood that carries hormones and metabolites around the body.

Detailed Description
-----------------
Regular exercise is associated with a reduced risk of developing colon cancer. However, the mechanisms underpinning the anti-cancer effect of exercise are not yet fully understood. A recent theory suggests that each time you exercise, the short-lasting spikes in circulating hormones can suppress the growth of cancer cells. Hence, every exercise bout could have a direct anti-cancer effect. This study will recruit men with an increased of colon cancer and explore whether incubating colon cancer cells with serum collected after a bout of moderate-intensity aerobic exercise influences cell viability in vitro.

Official Title
-----------------
Effect of a Single Bout of Moderate-intensity Aerobic Exercise on Colon Cancer Cell Growth in Vitro

Conditions
-----------------
Colon Adenocarcinoma, Colon Cancer

Intervention / Treatment
-----------------
* Other: Exercise assessment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥ 50 years BMI ≥ 25 kg/m2 and/or waist circumference of ≥ 94 cm Male Participating in less than 30 min of planned, structured, moderate to vigorous-intensity physical activity on three or more d·wk-1 for the last three months Exclusion Criteria: Any absolute or relative contraindication to exercise testing, as determined by the American College of Sports Medicine Any sign/symptom of cardiovascular, metabolic or renal disease Known cardiovascular, metabolic or renal disease without written medical clearance from physician Resting hypertension (≥160 mmHg systolic and/or ≥90 mmHg diastolic) Chronic obstructive pulmonary disease and/or asthma with peak respiratory flow < 300 l/min Previous stroke or transient ischemic attack Epilepsy or aneurysm (large vessel or cerebral) Previous or current treatment for malignancy Clotting disorder Taking beta-adrenergic blocking agents Resting heart rate ≥ 100 bpm Musculoskeletal, neurological, anthropometric, or rheumatoid conditions that makes it not possible to pedal a bicycle and/or would be worsened due to exercise Body mass > 150 kg

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Crossover Assignment
Interventional Model Description: This is a randomised, counterbalanced, crossover study whereby all participants will complete an exercise assessment and a resting assessment in a randomised order.
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Exercise assessment<br>The exercise condition will involve venous blood samples being drawn immediately before and after a single bout of moderate-intensity aerobic interval exercise. | Other: Exercise assessment<br>* The moderate-intensity aerobic interval exercise will be performed on a cycle ergometer under the supervision of trained staff in an exercise science laboratory. Participants will perform a 5 to 10-minute warm-up that begins by pedalling against a light resistance (60 W) and progressively increases in resistance until a target heart rate of 50-60% heart rate reserve is achieved. Participants will then complete 6 x 5-minute bouts at 60% heart rate reserve whilst maintaining a cadence of 60 rev·min-1, separated by 2.5-minutes of pedalling against light resistance (60 W). The session will finish with a cool-down at light resistance (60 W) lasting 10-minutes.<br>|
| No Intervention: Resting assessment<br>The resting condition will involve venous blood samples being drawn before and after 60 minutes of seated rest. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cell viability (%) | Viability of a human colon cancer cell line (LoVo) will be assessed via quantification of the fluorescent signal by the resazurin assay (Sigma-Aldrich, Dorset, UK). Cells will be seeded in culture medium containing 10% serum from individual participants and incubated for 48 hours. Fluorescence will then be measured using a microplate reader at an excitation of 540 nm and emission of 590 nm. Background fluorescence will be subtracted from each well and then values will be normalised to fluorescence of control cells grown in 10% fetal bovine serum instead of participant serum to give a percent viability. | 48 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Concentration of epinephrine (pg/ml) | Systemic concentration of epinephrine will be measured from serum | Immediately before and immediately after the exercise and resting assessments | 
| Concentration of norepinephrine (pg/ml) | Systemic concentration of norepinephrine will be measured from serum | Immediately before and immediately after the exercise and resting assessments | 
| Concentration of Interleukin 6 (pg/ml) | Systemic concentration of Interleukin 6 will be measured from serum | Immediately before and immediately after the exercise and resting assessments | 
| Concentration of Tumour Necrosis Factor alpha (pg/ml) | Systemic concentration of Tumour Necrosis Factor alpha will be measured from serum | Immediately before and immediately after the exercise and resting assessments | 
| Concentration of Insulin (pmol/l) | Systemic concentration of Insulin will be measured from serum | Immediately before and immediately after the exercise and resting assessments | 
| Concentration of Insulin-like growth factor 1 (ng/ml) | Systemic concentration of Insulin-like growth factor 1 will be measured from serum | Immediately before and immediately after the exercise and resting assessments | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Colon cancer, Aerobic exercise